INSYS Therapeutics, Inc. (INSY) Can’t Burn Your Long Portfolio. Has Another Strong Session

April 17, 2018 - By Michael Collier

Investors sentiment decreased to 0.76 in 2017 Q4. Its down 0.49, from 1.25 in 2017Q3. It worsened, as 21 investors sold INSYS Therapeutics, Inc. shares while 29 reduced holdings. 20 funds opened positions while 18 raised stakes. 16.43 million shares or 9.75% less from 18.21 million shares in 2017Q3 were reported.
Northern Corporation holds 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 312,227 shares. State Of Wisconsin Inv Board has 19,000 shares. Community Commercial Bank Na accumulated 400 shares. Perigon Wealth Ltd Co holds 57 shares or 0% of its portfolio. Virtu Financial Limited Liability Corporation holds 0.01% in INSYS Therapeutics, Inc. (NASDAQ:INSY) or 20,061 shares. Schwab Charles Mgmt stated it has 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Dimensional Fund Advsr Lp holds 0% in INSYS Therapeutics, Inc. (NASDAQ:INSY) or 434,548 shares. Rhumbline Advisers invested 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). California Employees Retirement has 75,500 shares for 0% of their portfolio. Gam Ag has 0.02% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 83,940 shares. Tci Wealth has 0.03% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 7,766 shares. Reilly Advisors Ltd Liability Co reported 1,000 shares stake. New York State Common Retirement Fund invested in 0% or 22,700 shares. Eqis Mgmt reported 64,741 shares stake. Moreover, Goldman Sachs Grp Inc Inc has 0% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 117,676 shares.

The stock of INSYS Therapeutics, Inc. (NASDAQ:INSY) is a huge mover today! The stock increased 7.81% or $0.49 during the last trading session, reaching $6.76. About 991,955 shares traded or 29.33% up from the average. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 45.03% since April 17, 2017 and is downtrending. It has underperformed by 56.58% the S&P500.
The move comes after 7 months positive chart setup for the $498.65M company. It was reported on Apr, 17 by Barchart.com. We have $7.30 PT which if reached, will make NASDAQ:INSY worth $39.89 million more.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Ratings Coverage

Among 3 analysts covering Insys Therapeutics (NASDAQ:INSY), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. Insys Therapeutics had 4 analyst reports since October 18, 2017 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Wednesday, October 18. The rating was downgraded by PiperJaffray on Friday, March 9 to “Underweight”. On Friday, November 3 the stock rating was maintained by Jefferies with “Buy”. The firm has “Buy” rating by RBC Capital Markets given on Friday, October 27.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $498.65 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.